Pfizer’s Abrysvo Receives EC’s Marketing Authorization to Protect Infants through Maternal Immunization and Older Adults from RSV
Shots:
- The EC has granted marketing authorization for Abrysvo, the RSVpreF vaccine for older adults & for immunization of pregnant individuals to help protect their infants immediately from birth through 6mos.
- The authorization was based on the P-III study (RENOIR) in adults aged ≥60yrs. & (MATISSE) trial in infants born to healthy individuals vaccinated during pregnancy evaluating the efficacy, immunogenicity & safety of Abrysvo
- In the (RENOIR) study, the RSVpreF vaccine prevented RSV-associated LRTD and RSV-associated acute respiratory illness in adults aged ≥60yrs. while the vaccine administered during pregnancy in (MATISSE) trial was effective in infants with no safety concerns. The authorization is valid in all 27 EU member states, Iceland, Liechtenstein & Norway
Ref: Pfizer | Image: Pfizer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
